An increasing number of people are experiencing a range of neurodegenerative diseases – one of the saddest and most emotionally debilitating is Alzheimer’s Disease (AD).
A non-psychoactive phytocannabinoid called CBD (Cannabidiol) has demonstrated in a multitude of research studies that it has antioxidant, anti-inflammatory, and neuroprotective properties. Although many of these studies are done inside of a lab with test-tubes (in vitro), thousands of cases involving individuals can be documented – showing a wide range of potential applications for this cannabinoid (there are over 113 known cannabinoids in the cannabis or hemp plant).
From the Frontiers in Pharmacology article:
“Cannabidiol (CBD) is a non-psychoactive phytocannabinoid that has demonstrated neuroprotective, anti-inflammatory and antioxidant properties in vitro. Thus, it is investigated as a potential multifunctional treatment option for AD. Here, we summarize the current status quo of in vivo effects of CBD in established pharmacological and transgenic animal models for AD. The studies demonstrate the ability of CBD to reduce reactive gliosis and the neuroinflammatory response as well as to promote neurogenesis. Importantly, CBD also reverses and prevents the development of cognitive deficits in AD rodent models.”
Cannabis and/or non-psychoactive hemp has been used for thousands of years in a variety of applications – the United States federal government even holding a patent for cannabinoids’ antioxidant properties.
The momentum and applications of cannabinoids continues to grow – at That’s Natural, we encourage you to find a full-spectrum cannabinoid and terpene rich product that you can trust! We are here to protect your Food and Medicine Freedom!
Categories: Research on CBD (Cannabidiol)